全文获取类型
收费全文 | 9909篇 |
免费 | 530篇 |
国内免费 | 67篇 |
专业分类
耳鼻咽喉 | 64篇 |
儿科学 | 250篇 |
妇产科学 | 132篇 |
基础医学 | 1262篇 |
口腔科学 | 208篇 |
临床医学 | 627篇 |
内科学 | 2986篇 |
皮肤病学 | 129篇 |
神经病学 | 747篇 |
特种医学 | 365篇 |
外科学 | 1577篇 |
综合类 | 33篇 |
预防医学 | 266篇 |
眼科学 | 155篇 |
药学 | 658篇 |
中国医学 | 15篇 |
肿瘤学 | 1032篇 |
出版年
2023年 | 73篇 |
2022年 | 147篇 |
2021年 | 219篇 |
2020年 | 127篇 |
2019年 | 182篇 |
2018年 | 214篇 |
2017年 | 192篇 |
2016年 | 221篇 |
2015年 | 252篇 |
2014年 | 270篇 |
2013年 | 350篇 |
2012年 | 551篇 |
2011年 | 677篇 |
2010年 | 390篇 |
2009年 | 355篇 |
2008年 | 585篇 |
2007年 | 621篇 |
2006年 | 625篇 |
2005年 | 597篇 |
2004年 | 615篇 |
2003年 | 590篇 |
2002年 | 546篇 |
2001年 | 166篇 |
2000年 | 158篇 |
1999年 | 144篇 |
1998年 | 125篇 |
1997年 | 111篇 |
1996年 | 82篇 |
1995年 | 71篇 |
1994年 | 67篇 |
1993年 | 82篇 |
1992年 | 110篇 |
1991年 | 104篇 |
1990年 | 91篇 |
1989年 | 97篇 |
1988年 | 83篇 |
1987年 | 74篇 |
1986年 | 71篇 |
1985年 | 80篇 |
1984年 | 42篇 |
1983年 | 47篇 |
1982年 | 26篇 |
1981年 | 18篇 |
1980年 | 21篇 |
1979年 | 30篇 |
1978年 | 34篇 |
1977年 | 25篇 |
1972年 | 13篇 |
1969年 | 20篇 |
1968年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
H Kobashi A Nishioka N Miyamoto K Ohara T Okamoto 《The Japanese journal of antibiotics》1985,38(10):2932-2942
Ceftizoxime suppositories (CZX-S), containing 250 mg or 125 mg of CZX, were given to 6 children, 4 with acute bronchopneumonia and 2 with acute pharyngobronchitis, who were not suited to treatment with injectable or oral form of the drug. The clinical response was "good" in all the children and the causative organisms were eradicated in 2 children (H. influenzae or S. aureus). Adverse reactions consisted of 1 case each of diarrhea and transiently increased GPT. In conclusion, CZX-S proved to be highly effective in the treatment of bacterial infections in children. 相似文献
92.
The occurrence of a post-traumatic epidural hematoma in two patients with long-standing arrested hydrocephalus is reported. There was a relatively long interval between the head injury and the onset of symptoms. The large hematoma was accommodated by the decrease in size of the markedly dilated ventricles. This report stresses the possibility of the presence of an epidural hematoma in the management of head injury in patients with long-standing arrested hydrocephalus. 相似文献
93.
In a comparative study of MR images of 289 neurosurgical patients, loss of the signal intensity (signal void phenomenon) of CSF in the aqueduct was observed in 77 patients. This signal void phenomenon was seen most frequently in infants with chronic subdural hematoma (12 of 18) and patients of all age groups suffering from communicating hydrocephalus (10 of 14). It is known that CSF in the cranial cavity flows toward the spinal CSF space in to and fro manner responding to brain parenchyma pulsations. The velocity of this flow is to be faster in the narrower parts through the ventricular systems such as the aqueduct, Monro's foramen and the 4th ventricles. We think that in T2 weighted images signal void phenomenon reflects "high velocity signal loss" due to CSF flow. When the subarachnoid adhesions secondary to subarachnoid hemorrhage stagnate CSF flow in the subarachnoid space, the intraventricular CSF flow forms the main buffer for changes of the brain volume. This causes an increase in the amplitude of the pulsatile flow in the ventricular systems. Therefore the signal void phenomenon in the aqueductal CSF becomes more pronounced. It may be possible to differentiate normal circulation of CSF from abnormal with the bigger amplitude of CSF pulsatile flow, to understand the mechanisms of the normal pressure hydrocephalus or to diagnose a shunt malfunction. Therefore more insight in the CSF flow as imaged by MRI is needed, quantification of CSF flow will be the subjects of our further research. 相似文献
94.
Masaaki Iigo Masanori Miwa Hideo Ishitsuka Kazuo Nitta 《Cancer chemotherapy and pharmacology》1987,19(1):61-64
Summary The effect of inosine, guanosine, and guanosine 5-monophosphate (GMP) on the antitumor activity of 5-deoxy-5-fluorouridine (5-DFUR) was investigated using P388 leukemia and P815 mastocytoma.The antitumor activity of 5-DFUR was markedly enhanced by coadministration of inosine or guanosine. The increase in lifespan (ILS) of mice treated with 5-DFUR was augmented by the combination with guanosine or inosine in a dose-dependent fashion, and the maximum ILS was about 160% with the combination, while that in the case of 5-DFUR alone was only 48% in the P388 leukemia system. The therapeutic ratio (dose at ILSmax/dose at ILS30) of the combination with guanosine or inosine was 333 and 136, respectively, whereas that of 5-DFUR alone was 3.6. GMP also markedly potentiated the antitumor activity of 5-DFUR in both P388 leukemia and P815 mastocytoma systems, just as it potentiated the activity of 5-fluorouracil in the latter system.The uric acid level in the serum was elevated after IP injection of guanosine or inosine but the value was much lower in the case of guanosine than in inosine. 相似文献
95.
Kiyoji Kimura Ryuzo Ohno Ichita Amaki Kenichi Hattori Yutaka Hirota Akira Hoshino Michito Ichimaru Munemoto Ito Ikuo Kimura Tadashi Maekawa Toru Masaoka Toru Nakamura Makoto Ogawa Masao Oguro Kazuo Ohta Shigeyuki Osamura Masanori Shimoyama Fumimaro Takaku Yoshiro Uzuka Kazumasa Yamada 《Medical oncology (Northwood, London, England)》1986,3(1):15-24
A phase I study ofN 4-behenoyl-1-β-d-arabinofuranosylcytosine (BHAC) was conducted in 66 patients, 41 with solid tumors and 25 with hematological malignancies. The patients received either a 2-h single intravenous (i.v.) drip infusion (Schedule 1) or consecutive daily 2-h i.v. infusions (Schedule 2). In Schedule 1 the daily dose was initiated with 1.5 mg kg?1 which was escalated up to 7 mg kg?1. Side-effects were mild, and included nausea, vomiting, epilation, and hot flushes. Because of the presence of the solvent vehicle, HCO-60 and in consideration of the mechanism of action of BHAC, the dose escalation was stopped at 7 mg kg?1. In Schedule 2, the daily dose was started with 1.5 mg kg?1 which was escalated up to 8 mg kg?1 and given for 2–16 days. Myelosuppression was found to be dose-limiting toxicity. The maximum tolerated dose (MTD) in patients with non-hematological solid tumors was assumed to be 5 mg kg?1 daily × 5 days. The plasma disappearance curve of BHAC looked biphasic, and when 4 mg kg?1 of BHAC were administered the half-lives of the initial phase (t 1/2α) and the second phase (t 1/2β) were calculated as 0.798 and 5.76 h respectively. In Schedule 2 complete remission was observed in 5 out of 21 patients with acute leukemia, one partial remission in Hodgkin’s disease, and one 1-B response (Karnofsky) in thyroid papillary adenocarcinoma. 相似文献
96.
Carnitine is a naturally occurring amino acid derivative that is involved in the transport of long-chain fatty acids to the mitochondrial matrix. There, these substrates undergo β-oxidation, producing energy. The major sources of carnitine are dietary intake, although carnitine is also endogenously synthesized in the liver and kidney. However, in patients on dialysis, serum carnitine levels progressively fall due to restricted dietary intake and deprivation of endogenous synthesis in the kidney. Furthermore, serum-free carnitine is removed by hemodialysis treatment because the molecular weight of carnitine is small (161 Da) and its protein binding rates are very low. Therefore, the dialysis procedure is a major cause of carnitine deficiency in patients undergoing hemodialysis. This deficiency may contribute to several clinical disorders in such patients. Symptoms of dialysis-related carnitine deficiency include erythropoiesis-stimulating agent-resistant anemia, myopathy, muscle weakness, and intradialytic muscle cramps and hypotension. However, levocarnitine administration might replenish the free carnitine and help to increase carnitine levels in muscle. This article reviews the previous research into levocarnitine therapy in patients on maintenance dialysis for the treatment of renal anemia, cardiac dysfunction, dyslipidemia, and muscle and dialytic symptoms, and it examines the efficacy of the therapeutic approach and related issues. 相似文献
97.
Hara Masatoshi Tanaka Shigeru Torisu Kumiko Matsukuma Yuta Tsuchimoto Akihiro Tokumoto Masanori Ooboshi Hiroaki Nakano Toshiaki Tsuruya Kazuhiko Kitazono Takanari 《Clinical and experimental nephrology》2021,25(8):822-834
Clinical and Experimental Nephrology - A growing body of evidence has shown that non-alcoholic fatty liver disease (NAFLD) is associated with chronic kidney disease (CKD). Non-invasive fibrosis... 相似文献
98.
Miyake A Akagi T Enose Y Ueno M Kawamura M Horiuchi R Hiraishi K Adachi M Serizawa T Narayan O Akashi M Baba M Hayami M 《Journal of medical virology》2004,73(3):368-377
We have previously reported that concanavalin A-immobilized polystyrene nanospheres (Con A-NS) could efficiently capture HIV-1 particles and that intranasal immunization with inactivated HIV-1-capturing nanospheres (HIV-NS) induced vaginal anti-HIV-1 IgA antibody response in mice. In this study, to evaluate the protective effect of immunization, each three macaques was intranasally immunized with Con A-NS or inactivated simian/human immunodeficiency virus KU-2-capturing nanospheres (SHIV-NS) and then intravaginally challenged with a pathogenic virus, SHIV KU-2. After a series of six immunizations, vaginal anti-HIV-1 gp120 IgA and IgG antibodies were detected in all SHIV-NS-immunized macaques. After intravaginal challenge, one of the three macaques in each of the Con A-NS- and SHIV-NS-immunized groups was infected. Plasma viral RNA load of infected macaque in SHIV-NS-immunized macaques was substantially less than that in unimmunized control macaque and reached below the detectable level. However, it could not be determined whether intranasal immunization with SHIV-NS is effective in giving complete protection against intravaginal challenge. To explore the effect of the SHIV-NS vaccine, the remaining non-infected macaques were rechallenged intravenously with SHIV KU-2. After intravenous challenge, all macaques became infected. However, SHIV-NS-immunized macaques had lower viral RNA loads and higher CD4(+) T cell counts than unimmunized control macaques. Plasma anti-HIV-1 gp120 IgA and IgG antibodies were induced more rapidly in the SHIV-NS-immunized macaques than in the controls. The rapid antibody responses having neutralizing activity might contribute to the clearance of the challenge virus. Thus, SHIV-NS-immunized macaques exhibited partial protection to vaginal and systemic challenges with SHIV KU-2. 相似文献
99.
K Ohara S Sugahara T Yoshida K Matsueda K Kuramoto M Akisada 《Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica》1990,50(2):146-154
Radiation tolerance of the partially irradiated liver was studied in eight patients with primary hepatoma treated by a multimodal approach. Seven patients were treated by transarterial embolization therapy (TAE) with Lipiodol-MMC, and two patients were treated by operation, combined with radiotherapy. Six patients had liver cirrhosis and the other one had renal dysfunction. Respiration-gated irradiation was employed to reduce a treatment volume for seven patients. Radiation portals were carefully tailored using the embolized Lipiodol or a metal clip inserted into the tumor as references. Two or three portals were used for each patient. The treatment volume ranged from 64 to 1400 cm3. The target dose ranged from 50.4 Gy to 81.0 Gy, from 73.5 to 108.6 in TDF. Liver function tests (GOT, GPT, LDH, ALP, ChE and total Bilirubin) were examined for 30 weeks after initiation of irradiation. Three patients showed abnormal value in more than 5 tests. Of these three patients, the hepatic hilum was included in the treatment volume in two, and the tumor progressed during the observation period in two. Leukopenia and thrombopenia were observed, but these values were not below 2000 and 40000/mm3, respectively, although the thrombocyte count before irradiation was below 100000/mm3 in 7 patients. AFP titers decreased after the treatment in six out of seven patients with abnormally elevated pretreatment titer. The survival period after staring irradiation was 6.5 to 25 months. "The volume dose" did not correlate well with the degree of the liver function aggravation.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
100.
Hirokazu Tsukahara Masahiro Hiraoka Masanori Kurivama Masakazu Saito Kiyoshi Morikawa Mitsuhiko Kuroda Toshiro Tominaga Masakatsu Sudo 《Pediatric nephrology (Berlin, Germany)》1993,7(2):199-201
Urinary 1-microglobulin (U-A1M) was measured in healthy term infants on days 1, 4, 7, 14, 28, 90 and 180 of life. U-A1M was high until day 14 and declined thereafter. It was significantly correlated with urinary 2-microglobulin (U-B2M) throughout the study, but not with serum A1M on days 1 or 7. Similar to U-B2M, U-A1M in the clinically stable term infants with intrauterine growth retardation (n=4–7) was not elevated on days 1–7. In the sick infants who needed immediate resuscitatio at birth (n=4–8), U-A1M as well as U-B2M was high on days 1–7 and then decreased to normal levels, suggesting that U-A1M can be used as a sensitive marker of acute proximal tubular damage and its recovery. These observations indicate that U-A1M is a useful index of proximal tubular function in early infancy. 相似文献